36076-20-7Relevant articles and documents
Inhibitors of nedd8-activating enzyme
-
Paragraph 0102, (2014/08/20)
The invention relates to an administration unit comprising crystalline form I of {(1 S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate (I-216) hydrochloride salt and to a packaging comprising the administration unit according to the invention.
HETEROCYCLIC INHIBITORS OF GLUTAMINASE
-
Page/Page column 114, (2013/06/06)
The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases using the heterocyclic compounds of the invention.
Enzymatic desymmetrization route to ethyl [3-(2-amino-2-methylpropyl) phenyl]acetate
De Koning, Pieter D.,Gladwell, Iain R.,Morrison, Natalie A.,Moses, Ian B.,Panesar, Maninder S.,Pettman, Alan J.,Thomson, Nicholas M.,Yazbeck, Daniel R.
, p. 871 - 875 (2012/06/18)
An efficient process to ethyl [3-(2-amino-2-methylpropyl)phenyl]acetate 6 has been developed. Key steps include a novel enzymatic desymmetrization of diester 2 and a Ritter reaction between alcohol 4 and chloroacetonitrile, followed by chemoselective deprotection with thiourea.